FDA Review Of Dietary Ingredients For Pharmacy Compounding Could Open Door To Change DSHEA
This article was originally published in The Rose Sheet
FDA could look for Congress to amend DSHEA as it creates a “deep” administrative record on dietary ingredients placed on a list of substances no longer allowed for use by compounding pharmacies, says integrative medicine attorney Alan Dumoff. Pharmacy organizations are writing a citizen petition to ward off what they fear will be an excuse to step-up regulation of supplement manufacturing and marketing.
You may also be interested in...
FTC Bureau of Consumer Protection official Richard Cleland takes on the hot-button issue by explaining that a supplement health or structure/function claim doesn't need support from research with the size and scope of studies looking at the safety and efficacy of a drug ingredient proposed for a certain indication. Supplement ad claims, though, still need competent and reliable scientific evidence as support.
Will lessons from New England Compounding Center ever be learned? Top FDA officials say that compounding pharmacies need up their game and do a better job of producing quality sterile drugs as way too many facilities are failing GMP inspections and producing drugs that are sickening – and even killing – patients. Officials say forthcoming final guidance and final USP standard should turn this situation around.
Gottlieb is not the first FDA commissioner nominee to profess support for its regulatory framework established by DSHEA, but the focus of Hatch's question serves stronger notice than similar questions asked of previous candidates that the agency authority to enforce in the space does need adjustment.